Glucagen Hypokit (Glucagon)

Glucagen Hypokit is a glucagon injectable solution marketed in the EU. It contains the peptide hormone glucagon as the active ingredient, supplied in a ready‑to‑use hypodermic kit. The product is prescribed for emergency treatment of severe hypoglycemia and is administered by intramuscular or subcutaneous injection. It belongs to the antihypoglycemic therapeutic class and is regulated as a prescription‑only medication in the European Union for adult patients.

Glucagen Hypokit is indicated for the rapid reversal of severe hypoglycemia when oral carbohydrate intake is not possible or effective.

- Adults and children with type 1 or type 2 diabetes experiencing a blood glucose level below 50 mg/dL (2.8 mmol/L). - Emergency treatment of hypoglycemic episodes occurring during insulin therapy, including insulin pump failure. - Use by caregivers, healthcare professionals, or trained individuals in outpatient or home settings. - Administration when the patient is unconscious, unable to swallow, or having seizures due to low glucose. - Situations where rapid glucose elevation is required to prevent neurological damage.

The safety profile of Glucagen Hypokit reflects the known pharmacology of glucagon, with most reactions being mild and transient.

Common: - Nausea or vomiting - Flushing or warmth at the injection site - Transient headache - Mild abdominal discomfort

Serious: - Allergic reaction such as rash, itching, or angioedema - Severe hypotension or cardiovascular collapse (rare) - Pancreatitis (very rare)

Before using Glucagen Hypokit, clinicians should assess patient history and consider specific safety considerations to minimize risks.

- Confirm severe hypoglycemia and inability to ingest oral glucose before injection. - Use caution in patients with known glucagon allergy or pheochromocytoma. - Avoid repeated dosing within a short interval; monitor glucose after administration. - Pregnancy and lactation status are not well established; weigh benefits against potential risks. - Patients with cardiovascular disease may experience transient blood pressure changes. - Store the kit at controlled room temperature and protect from light.

Glucagen Hypokit may interact with certain medications or clinical conditions, influencing its effectiveness or safety.

Avoid: - Beta‑blockers, which can mask typical glucagon‑induced tachycardia. - Insulin secretagogues administered immediately after glucagon, potentially causing rebound hypoglycemia.

Use with caution: - Oral contraceptives or estrogen therapy, as glucagon can affect hormone metabolism. - Drugs that alter hepatic glycogen stores (e.g., corticosteroids). - Medications that affect cardiovascular tone, such as nitrates.